{
    "clinical_study": {
        "@rank": "107407", 
        "acronym": "OKN-007", 
        "arm_group": {
            "arm_group_label": "All patients", 
            "arm_group_type": "Experimental", 
            "description": "All participants enrolled in this study"
        }, 
        "brief_summary": {
            "textblock": "This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot\n      cohort of human recurrent malignant glioma patients. All patients will have been previously\n      treated with the standard-of-care treatment which includes surgical resection, radiation and\n      chemotherapy, and in some cases treatment for recurrent disease with investigational agents\n      or bevacizumab (Avastin). Patients with unequivocal recurrence (first or greater)\n      established by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine\n      pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007\n      treatment on this protocol."
        }, 
        "brief_title": "Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Malignant Glioma", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Confirmed histopathology of WHO grade III glioma or WHO grade IV GBM at primary\n             diagnosis\n\n          2. Unequivocal radiographic evidence of tumor progression by MRI within 14 days prior to\n             registration\n\n          3. Prior radiotherapy\n\n          4. Prior Temozolomide treatment\n\n          5. Last cytotoxic chemotherapy 28 or more days or biologic therapy treatment 14 or more\n             days before study start (greater than or equal to 42 days if nitrosourea was\n             administered)\n\n          6. Karnofsky performance status greater than or equal to 60%\n\n          7. Full recovery (< grade 1) from the toxic effects of any earlier intervention and a\n             minimum of 28 days from the administration of any investigational agent\n\n          8. Adequate renal, liver and bone marrow function:\n\n               -  Leukocytes >3,000/mcL\n\n               -  Absolute neutrophil count >1,500/mcL\n\n               -  Platelets >100,000/mcL\n\n               -  Total bilirubin within normal limits\n\n               -  AST / ALT (SGPT) <2.5 x ULN\n\n               -  Creatinine within normal limits\n\n          9. Patients must be >_18 years of age\n\n        Exclusion Criteria:\n\n          1. Second primary malignancy (except adequately treated basal cell carcinoma of the\n             skin). Patients who had another malignancy in the past, but have been free of active\n             disease for more than 2 years, are eligible\n\n          2. Have received treatment within the last 28 days with a drug that has not received\n             regulatory approval for any indication at the time of study entry\n\n          3. Serious concomitant systemic disorders (for example, active infection or abnormal\n             electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the\n             investigator, would compromise the safety of the patient and his/her ability to\n             complete the study\n\n          4. Patients with moderate or severe renal impairment (calculated creatinine clearance of\n             < 60 mL/min)\n\n          5. Patients with sodium, potassium, or creatinine serum electrolytes > grade 2.\n\n          6. Patients with PT/PTT above the upper limit of normal\n\n          7. Screening ECG abnormality documented by the investigator as medically significant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672463", 
            "org_study_id": "HCI57337"
        }, 
        "intervention": {
            "arm_group_label": "All patients", 
            "description": "Dose escalation/PK cohort:  20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.\nExpansion cohort:  MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.", 
            "intervention_name": "OKN-007", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Kimberly Benjamin, RN", 
                    "phone": "405-271-8778", 
                    "phone_ext": "48876"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "Oklahoma University"
                }, 
                "investigator": {
                    "last_name": "Alexandra Ikeguchi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "Huntsman Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Randy Jensen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients", 
        "overall_contact": {
            "email": "britney.hall@hci.utah.edu", 
            "last_name": "Britney Hall", 
            "phone": "801-213-4395"
        }, 
        "overall_official": {
            "affiliation": "Huntsman Cancer Institute", 
            "last_name": "Randy Jensen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to determine MTD, tolerance, and safety of OKN-007 in patients with recurrent GBM and anaplastic glioma.", 
            "measure": "Number of Adverse events per patient", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672463"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine drug levels of OKN-007 in blood.", 
                "measure": "PK level in participants", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "To determine radiographic response rate and 6 month Progression-Free Survival (PFS) of patients treated with OKN-007. PFS is defined as the time from first drug treatment until objective tumor progression or death.", 
                "measure": "6 month progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "University of Utah", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Utah", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}